Cancer Epidemiology
Volume 34, Issue 2 , Pages 184-188 , April 2010

Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer

  • Fatma Trifa

      Affiliations

    • Unité de Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP « 1177 », 3018 Sfax, Tunisia
    • ,
  • Sondes Karray-Chouayekh

      Affiliations

    • Unité de Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP « 1177 », 3018 Sfax, Tunisia
    • ,
  • Imed Mabrouk

      Affiliations

    • Unité de Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP « 1177 », 3018 Sfax, Tunisia
    • ,
  • Sami Baccouche

      Affiliations

    • Unité de Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP « 1177 », 3018 Sfax, Tunisia
    • ,
  • Abdelmajid Khabir

      Affiliations

    • Centre Hospitalo-Universitaire Habib Bourguiba, 3000 Sfax, Tunisia
    • ,
  • Tahia Sellami-Boudawara

      Affiliations

    • Centre Hospitalo-Universitaire Habib Bourguiba, 3000 Sfax, Tunisia
    • ,
  • Ali Gargouri

      Affiliations

    • Unité de Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP « 1177 », 3018 Sfax, Tunisia
    • ,
  • Raja Mokdad-Gargouri

      Affiliations

    • Unité de Génétique du cancer et Production de protéines thérapeutiques, Centre de Biotechnologie de Sfax, route Sidi Mansour, BP « 1177 », 3018 Sfax, Tunisia
    • Corresponding Author InformationCorresponding author. Tel.: +216 74 874 449.

,Accepted 13 February 2010.

References 

  1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53
  2. Hainaut P, Hollstein M. p53 and human cancer: the first thousand mutations. Adv Cancer Res. 2000;77:81–137
  3. Olivier M, Eclcs R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607–614
  4. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;3:357–365
  5. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954–1956
  6. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94:681–690
  7. Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res. 2000;60:1062–1069
  8. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32
  9. Runnebaum IB, Tong XW, Konig R, Zhao H, Korner K, Atkinson EN, et al. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet. 1995;345:994
  10. Khaliq S, Hameed A, Khaliq T, Ayub Q, Qamar R, Mohyuddin A, et al. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test. 2000;4:23–29
  11. Osorio A, Pollán M, Pita G, Schmutzler RK, Versmold B, Engel C, et al. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2008;99:974–977
  12. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–963
  13. Buyru N, Tigli H, Dalay N. p53 codon 72 polymorphism in breast cancer. Oncol Rep. 2003;10:711–714
  14. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16:2205–2208
  15. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100
  16. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004;23:3328–3337
  17. Pim D, Banks L. p53 polymorphic variants at codon 72 exerts different effects on cell cycle progression. Int J Cancer. 2004;108:196–199
  18. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481–1486
  19. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SMF, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10:772–784
  20. Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case–control studies. Breast Cancer Res Treat. 2009;
  21. Dai S, Mao C, Jiang L, Wang G, Cheng H. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case–control studies. Hum Genet. 2009;125:633–638
  22. Buller RE, Skilling JS, Kaliszewski S, Niemann T, Anderson B. Absence of significant of germ line p53 mutations in ovarian cancer patients. Gynecol Oncol. 1995;58:368–374
  23. Varley JM, McGown G, Thorncraft M, Kelsey AM, Birch JM. Significance of intron 6 sequence variations in the TP53 gene in Li- Fraumeni syndrome. Cancer Genet Cytogenet. 2001;29:85–87
  24. Fiszer-Maliszewska L, Kazanowska B, Kusnierczyk P, Manczak M, Nicpieklo W, Pachron-Zeman B, et al. Is p53 intronic variant G13964C associated with predisposition to cancer?. J Appl Genet. 2003;44:547–552
  25. Goldman R, Shields PG. Molecular epidemiology of breast cancer. In Vivo. 1998;12:43–48
  26. Stratton MR, Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505–10.
  27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988;16:1215
  28. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet. 1995;59:97–105
  29. Buyru N, Altinisik J, Demokan S, Dalay N. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev. 2007;31:207–213
  30. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–1316
  31. De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, Pensotti V, et al. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev. 2008;32:140–143
  32. Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer. 2003;103:431–433
  33. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, et al. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:105–112
  34. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang- Claude J. Intron 3 16bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002;12:269–272
  35. Papadakis E, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer. 2002;87:1013–1018
  36. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, et al. P53 germline haplotypes associated with increased risk for colorectal cancer. Carcinogenesis. 1995;16:1461–1464
  37. Lancester JM, Brownlee HA, Wiseman RW, Taylor J. p53 poymorphism in ovarian and bladder cancer. Lancet. 1995;346:182
  38. Papadakis EN, Dokianakis DN, Spandidos DA. p53 Codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun. 2000;3:389–392
  39. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev. 2006;30:523–529
  40. Hadhri-Guiga B, Toumi N, Khabir A, Sellami-Boudawara T, Ghorbel A, Daoud J, et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet Cytogenet. 2007;178:89–93
  41. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 2004;210:151–157
  42. Singh V, Rastogi N, Mathur N, Singh K, Singh MP. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol. 2008;18:48–57
  43. Baccouche S, Mabrouk I, Said S, Mosbah A, Jlidi R, Gargouri A. A more accurate detection of codon 72 polymorphism and LOH of the TP53 gene. Cancer Lett. 2003;189:91–96
  44. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 2007;173:38–42
  45. Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, Pupo GM, et al. The intronic G13964C variant in p53 is not a high risk mutation in familial breast cancer in Australia. Breast Cancer Res. 2001;3:346–349
  46. Osorio A, Martinez-Delgado B, Pollan M, Cuadros M, Urioste M, Torrenteras C, et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat. 2006;27:242–248
  47. Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, et al. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer. 2008;8:1–9
  48. Gallì P, Cadoni G, Volante M, De Feo E, Amore R, Giorgio A, et al. A case–control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer. 2009;9:1–9

PII: S1877-7821(10)00026-3

doi: 10.1016/j.canep.2010.02.007

Cancer Epidemiology
Volume 34, Issue 2 , Pages 184-188 , April 2010

Article Tools